A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 427 participants.

Also called NCT02992288

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 427 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02992288
  • EudraCT 2016-003839-38
Other papers using this trial's data
  • Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial European journal of heart failure, 2019-11 DOI, PubMed 31523892

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Bulgaria, Germany, Greece, Israel, Italy, Japan, Netherlands, Poland, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02992288. Randomized; quadruple masking; primary purpose treatment. Start 2017-02-22 (actual); primary completion 2018-03-28 (actual). Results posted on 2019-04-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction
Acronym
PANTHEON
Condition
Heart Failure
Intervention (Drug)
Neladenoson bialanate (BAY1067197)
Intervention (Drug)
Neladenoson bialanate (BAY1067197)
Intervention (Drug)
Neladenoson bialanate (BAY1067197)
Intervention (Drug)
Neladenoson bialanate (BAY1067197)
Intervention (Drug)
Neladenoson bialanate (BAY1067197)
Intervention (Drug)
Placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct02992288
Content hash
1dda11d5a824d543bd197b21d3372f46950b81670db2c0a9c349905a17dda90c